Asthma & COPD Combination Medication - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB509247251

Publication Date:

September 26, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

IT Services [2]

Computing & Electronics [3]

Description:

The global market for Asthma & COPD Combination Medication was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Asthma & COPD Combination Medication, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Asthma & COPD Combination Medication by region & country, by Type, and by Application.
The Asthma & COPD Combination Medication market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Asthma & COPD Combination Medication.
Market Segmentation
By Company
AstraZeneca
GSK
Boehringer Ingelheim Pharmaceuticals
Sunovion Pharmaceuticals Inc
Novartis
Circassia Pharmaceuticals Inc
Segment by Type:
Budesonide
LAMA/LABA Combo
Fluticasone/Salmeterol
Segment by Application
Moderate COPD
Severe COPD
Asthma
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Asthma & COPD Combination Medication manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Asthma & COPD Combination Medication in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Asthma & COPD Combination Medication in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Market Overview
1.1 Asthma & COPD Combination Medication Product Introduction
1.2 Global Asthma & COPD Combination Medication Market Size Forecast
1.3 Asthma & COPD Combination Medication Market Trends & Drivers
1.3.1 Asthma & COPD Combination Medication Industry Trends
1.3.2 Asthma & COPD Combination Medication Market Drivers & Opportunity
1.3.3 Asthma & COPD Combination Medication Market Challenges
1.3.4 Asthma & COPD Combination Medication Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Asthma & COPD Combination Medication Players Revenue Ranking (2023)
2.2 Global Asthma & COPD Combination Medication Revenue by Company (2019-2024)
2.3 Key Companies Asthma & COPD Combination Medication Manufacturing Base Distribution and Headquarters
2.4 Key Companies Asthma & COPD Combination Medication Product Offered
2.5 Key Companies Time to Begin Mass Production of Asthma & COPD Combination Medication
2.6 Asthma & COPD Combination Medication Market Competitive Analysis
2.6.1 Asthma & COPD Combination Medication Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Asthma & COPD Combination Medication Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Asthma & COPD Combination Medication as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Budesonide
3.1.2 LAMA/LABA Combo
3.1.3 Fluticasone/Salmeterol
3.2 Global Asthma & COPD Combination Medication Sales Value by Type
3.2.1 Global Asthma & COPD Combination Medication Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Asthma & COPD Combination Medication Sales Value, by Type (2019-2030)
3.2.3 Global Asthma & COPD Combination Medication Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Moderate COPD
4.1.2 Severe COPD
4.1.3 Asthma
4.2 Global Asthma & COPD Combination Medication Sales Value by Application
4.2.1 Global Asthma & COPD Combination Medication Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Asthma & COPD Combination Medication Sales Value, by Application (2019-2030)
4.2.3 Global Asthma & COPD Combination Medication Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Asthma & COPD Combination Medication Sales Value by Region
5.1.1 Global Asthma & COPD Combination Medication Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Asthma & COPD Combination Medication Sales Value by Region (2019-2024)
5.1.3 Global Asthma & COPD Combination Medication Sales Value by Region (2025-2030)
5.1.4 Global Asthma & COPD Combination Medication Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Asthma & COPD Combination Medication Sales Value, 2019-2030
5.2.2 North America Asthma & COPD Combination Medication Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Asthma & COPD Combination Medication Sales Value, 2019-2030
5.3.2 Europe Asthma & COPD Combination Medication Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Asthma & COPD Combination Medication Sales Value, 2019-2030
5.4.2 Asia Pacific Asthma & COPD Combination Medication Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Asthma & COPD Combination Medication Sales Value, 2019-2030
5.5.2 South America Asthma & COPD Combination Medication Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Asthma & COPD Combination Medication Sales Value, 2019-2030
5.6.2 Middle East & Africa Asthma & COPD Combination Medication Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Asthma & COPD Combination Medication Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Asthma & COPD Combination Medication Sales Value
6.3 United States
6.3.1 United States Asthma & COPD Combination Medication Sales Value, 2019-2030
6.3.2 United States Asthma & COPD Combination Medication Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Asthma & COPD Combination Medication Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Asthma & COPD Combination Medication Sales Value, 2019-2030
6.4.2 Europe Asthma & COPD Combination Medication Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Asthma & COPD Combination Medication Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Asthma & COPD Combination Medication Sales Value, 2019-2030
6.5.2 China Asthma & COPD Combination Medication Sales Value by Type (%), 2023 VS 2030
6.5.3 China Asthma & COPD Combination Medication Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Asthma & COPD Combination Medication Sales Value, 2019-2030
6.6.2 Japan Asthma & COPD Combination Medication Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Asthma & COPD Combination Medication Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Asthma & COPD Combination Medication Sales Value, 2019-2030
6.7.2 South Korea Asthma & COPD Combination Medication Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Asthma & COPD Combination Medication Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Asthma & COPD Combination Medication Sales Value, 2019-2030
6.8.2 Southeast Asia Asthma & COPD Combination Medication Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Asthma & COPD Combination Medication Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Asthma & COPD Combination Medication Sales Value, 2019-2030
6.9.2 India Asthma & COPD Combination Medication Sales Value by Type (%), 2023 VS 2030
6.9.3 India Asthma & COPD Combination Medication Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 AstraZeneca
7.1.1 AstraZeneca Profile
7.1.2 AstraZeneca Main Business
7.1.3 AstraZeneca Asthma & COPD Combination Medication Products, Services and Solutions
7.1.4 AstraZeneca Asthma & COPD Combination Medication Revenue (US$ Million) & (2019-2024)
7.1.5 AstraZeneca Recent Developments
7.2 GSK
7.2.1 GSK Profile
7.2.2 GSK Main Business
7.2.3 GSK Asthma & COPD Combination Medication Products, Services and Solutions
7.2.4 GSK Asthma & COPD Combination Medication Revenue (US$ Million) & (2019-2024)
7.2.5 GSK Recent Developments
7.3 Boehringer Ingelheim Pharmaceuticals
7.3.1 Boehringer Ingelheim Pharmaceuticals Profile
7.3.2 Boehringer Ingelheim Pharmaceuticals Main Business
7.3.3 Boehringer Ingelheim Pharmaceuticals Asthma & COPD Combination Medication Products, Services and Solutions
7.3.4 Boehringer Ingelheim Pharmaceuticals Asthma & COPD Combination Medication Revenue (US$ Million) & (2019-2024)
7.3.5 Sunovion Pharmaceuticals Inc Recent Developments
7.4 Sunovion Pharmaceuticals Inc
7.4.1 Sunovion Pharmaceuticals Inc Profile
7.4.2 Sunovion Pharmaceuticals Inc Main Business
7.4.3 Sunovion Pharmaceuticals Inc Asthma & COPD Combination Medication Products, Services and Solutions
7.4.4 Sunovion Pharmaceuticals Inc Asthma & COPD Combination Medication Revenue (US$ Million) & (2019-2024)
7.4.5 Sunovion Pharmaceuticals Inc Recent Developments
7.5 Novartis
7.5.1 Novartis Profile
7.5.2 Novartis Main Business
7.5.3 Novartis Asthma & COPD Combination Medication Products, Services and Solutions
7.5.4 Novartis Asthma & COPD Combination Medication Revenue (US$ Million) & (2019-2024)
7.5.5 Novartis Recent Developments
7.6 Circassia Pharmaceuticals Inc
7.6.1 Circassia Pharmaceuticals Inc Profile
7.6.2 Circassia Pharmaceuticals Inc Main Business
7.6.3 Circassia Pharmaceuticals Inc Asthma & COPD Combination Medication Products, Services and Solutions
7.6.4 Circassia Pharmaceuticals Inc Asthma & COPD Combination Medication Revenue (US$ Million) & (2019-2024)
7.6.5 Circassia Pharmaceuticals Inc Recent Developments
8 Industry Chain Analysis
8.1 Asthma & COPD Combination Medication Industrial Chain
8.2 Asthma & COPD Combination Medication Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Asthma & COPD Combination Medication Sales Model
8.5.2 Sales Channel
8.5.3 Asthma & COPD Combination Medication Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

AstraZeneca
GSK
Boehringer Ingelheim Pharmaceuticals
Sunovion Pharmaceuticals Inc
Novartis
Circassia Pharmaceuticals Inc

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂